Paul Eckburg
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Paul Eckburg
AN2 Therapeutics, Inc. reported in an 8-K filed August 8, 2024 that Paul Eckburg was terminated as Chief Medical Officer, effective August 30, 2024. The proxy statement of AN2 Therapeutics, Inc. reports total compensation of $946,501 for Paul Eckburg in fiscal 2024, including a base salary of $325,500. Disclosed compensation is on record for 4 fiscal years.
“Paul Eckburg, M.D., the Company's Chief Medical Officer, will depart the Company effective as of August 30, 2024 (the "Transition Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
AN2 Therapeutics, Inc. (ANTX)
Proxy statement
Start not stated–2024-08-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | AN2 Therapeutics, Inc. (ANTX) | Former Chief Medical Officer | $325,500 | $946,501 |
| 2023 | AN2 Therapeutics, Inc. (ANTX) | Former Chief Medical Officer | $465,000 | $1,453,786 |
| 2022 | AN2 Therapeutics, Inc. (ANTX) | Chief Medical Officer | $427,399 | $1,393,156 |
| 2021 | AN2 Therapeutics, Inc. (ANTX) | Chief Medical Officer | $258,125 | $903,053 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.